Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078 health care workers.
anti-SARS CoV-2 mRNA BNT162b2 vaccination
health care workers
self-reported symptoms
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
17
03
2021
revised:
03
05
2021
accepted:
04
05
2021
entrez:
7
6
2021
pubmed:
8
6
2021
medline:
8
6
2021
Statut:
ppublish
Résumé
Health care workers (HCWs) are at high risk of contracting an infection by SARS CoV-2 and thus they are a priority for vaccination. We hereby aim to investigate whether the risk of severe and moderate systemic symptoms (MSS) after vaccination is higher in HCWs with a history of previous COVID-19. An online questionnaire was offered to the cohort all HCWs undergoing anti-SARS CoV-2 mRNA BNT162b2 vaccination between January 4th and February 9th 2021 in two large tertiary hospitals (ASST Santi Paolo and Carlo) in Milan, Italy. Previous SARS-CoV-2 infection/COVID-19 was recorded. Local and systemic symptoms after each of the two doses were reported. MSS were those either interfering with daily activities or resulting in time off-work. Factors associated to MSS were identified by logistic regression. 3,078 HCW were included. Previous SARS-CoV-2 infection/COVID-19 occurred in 396 subjects (12·9%). 59·6% suffered from Our data confirm in a real-world setting, the lack of severe adverse events and the short duration of reactogenicity in already infected HCWs. Possible differences in immune reactivity are drivers of MSS among this group of HCWs, as well as among females and younger individuals. None.
Sections du résumé
BACKGROUND
BACKGROUND
Health care workers (HCWs) are at high risk of contracting an infection by SARS CoV-2 and thus they are a priority for vaccination. We hereby aim to investigate whether the risk of severe and moderate systemic symptoms (MSS) after vaccination is higher in HCWs with a history of previous COVID-19.
METHODS
METHODS
An online questionnaire was offered to the cohort all HCWs undergoing anti-SARS CoV-2 mRNA BNT162b2 vaccination between January 4th and February 9th 2021 in two large tertiary hospitals (ASST Santi Paolo and Carlo) in Milan, Italy. Previous SARS-CoV-2 infection/COVID-19 was recorded. Local and systemic symptoms after each of the two doses were reported. MSS were those either interfering with daily activities or resulting in time off-work. Factors associated to MSS were identified by logistic regression.
FINDINGS
RESULTS
3,078 HCW were included. Previous SARS-CoV-2 infection/COVID-19 occurred in 396 subjects (12·9%). 59·6% suffered from
INTERPRETATION
CONCLUSIONS
Our data confirm in a real-world setting, the lack of severe adverse events and the short duration of reactogenicity in already infected HCWs. Possible differences in immune reactivity are drivers of MSS among this group of HCWs, as well as among females and younger individuals.
FUNDING
BACKGROUND
None.
Identifiants
pubmed: 34095793
doi: 10.1016/j.eclinm.2021.100914
pii: S2589-5370(21)00194-2
pmc: PMC8165130
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100914Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
None of the authors have any conflicts of interest to disclose
Références
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Elife. 2019 May 14;8:
pubmed: 31084714
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
N Engl J Med. 2021 Feb 18;384(7):643-649
pubmed: 33378605
JAMA. 2021 Feb 23;325(8):780-781
pubmed: 33475702
Front Immunol. 2020 Oct 20;11:580987
pubmed: 33193384
AIDS. 2000 Mar 31;14(5):499-507
pubmed: 10780712
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3
pubmed: 32320677
Euro Surveill. 2021 Feb;26(6):
pubmed: 33573712
J Infect. 2021 Mar;82(3):378-383
pubmed: 33450302
Expert Rev Clin Pharmacol. 2011 Jul;4(4):453-66
pubmed: 22114855
Clin Microbiol Infect. 2021 Jan 20;:
pubmed: 33359539
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Med Virol. 2020 Oct;92(10):2050-2054
pubmed: 32383183
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279